Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand.
Exagen Inc. (XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a clinical trial in collaboration with Duke University in Durham, NC. The Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living with lupus. This prospective study will evaluate biomarkers, including the AVISE panel and Cell-Bound Complement Activation Products (CB-CAPs), that distinguish between changes in subsets of lupus patients with Type 1 and Type 2 systemic lupus erythematosus (SLE) activity.
Earlier today, Exagen Inc. released financial results for the quarter ended March 31, 2020. Ron Rocca, president and chief executive officer; and Kamal Adawi, chief financial officer, will host this afternoon's call.